Hong Kong Building Stock News

Why MMG’s latest guidance matters for shareholders MMG (SEHK:1208) has issued fresh guidance on its 2025 earnings and production plans, giving you clearer visibility on expected profitability and output across its core copper and zinc operations. The company is guiding for unaudited 2025 net profit after tax attributable to equity holders of US$500 million to US$520 million, alongside detailed volume targets at Las Bambas, Kinsevere, Khoemacau, Dugald River and Rosebery. See our latest...

Lingbao Gold Group Company Ltd. recently appointed corporate law expert Mr. Huang Hui as an independent non-executive director, while shareholders approved amendments to the company’s Articles of Association at an extraordinary general meeting on 22 January 2026. By combining a governance-focused board appointment with refreshed constitutional documents, Lingbao Gold appears to be tightening its oversight and decision-making framework. Next, we will examine how these governance enhancements,...

If you are wondering whether Tencent Holdings is still priced attractively after recent swings, it helps to step back and look at what the current share price might be implying about its long term value. The stock most recently closed at HK$558.0, with a 7 day return of a 10.1% decline and a 30 day return of a 10.6% decline. The return over the last year sits at 34.7% and the 3 year return at 49.6%, while the 5 year return is a 17.9% decline. Recent market attention has focused on Tencent's...

In January 2026, MicroPort Scientific Corporation issued consolidated earnings guidance indicating a turnaround to profitability for 2025, forecasting a net profit of at least US$20 million versus an audited net loss of about US$268 million in 2024. This expected swing of very large magnitude in bottom-line performance highlights a significant shift in the company’s operational and financial trajectory. Next, we will examine how this anticipated return to profitability could influence...

Ascletis Pharma recently filed a follow-on equity offering of HK$843.54 million via a subsequent direct listing, issuing 69,256,000 ordinary shares at HK$12.18 each. The fundraising follows positive Phase III data for denifanstat in moderate-to-severe acne and progress with ASC30 in metabolic disease, underscoring Ascletis’s late-stage pipeline momentum. We’ll now explore how this combination of positive Phase III acne data and a sizable equity raise shapes Ascletis Pharma’s investment...

In January 2026, Chinese automaker BYD reported a 30% year-on-year drop in global vehicle sales to 210,051 units, its fifth consecutive monthly decline amid reduced government incentives for electric vehicles at home and abroad. This setback comes after BYD transformed itself over two decades from a battery specialist into China’s largest automaker, with very large increases in annual vehicle sales, revenue and net income between 2020 and 2024. We’ll now examine how this abrupt sales decline...

Interest in Geely Automobile Holdings (SEHK:175) has picked up after its affiliate Polestar announced a US$400 million equity investment from Sumitomo Mitsui Banking Corporation and Standard Chartered Bank (Hong Kong) Limited, structured with three year put option exit rights. See our latest analysis for Geely Automobile Holdings. At a share price of HK$15.92, Geely Automobile Holdings has seen a 1-month share price return decline of 9.55% and a year-to-date share price return decline of...

On 30 January 2026, Weichai Power announced the election of Zhang Weili as an independent non-executive director and Wang Yanlei as a non-executive director, alongside new audit and remuneration committee roles for Zhang. By refreshing its board and clarifying committee responsibilities, the company signaled an emphasis on governance transparency and oversight that may matter to long-term stakeholders. We’ll now examine how these governance and board-committee changes shape Weichai Power’s...

WuXi Biologics (Cayman) (SEHK:2269) has drawn fresh attention after entering into a license and research service agreement with Vertex Pharmaceuticals for trispecific T cell engagers targeting B cell mediated autoimmune diseases. See our latest analysis for WuXi Biologics (Cayman). Those fresh collaborations with Vertex, Sinorda and HanchorBio arrive as WuXi Biologics’ share price sits at HK$36.98, with a 1 month share price return of 13.64% and a 1 year total shareholder return of 87.91%...

SITC International Holdings recently issued unaudited earnings guidance for the year ended 31 December 2025, expecting profit attributable to shareholders of about US$1,200 million to US$1,230 million, supported by container shipping volume of around 3.85 million TEUs and an average freight rate of roughly US$753 per TEU. The company links this profit improvement to expanding Asian trade flows and its focus on higher-value shipping services rather than simply adding capacity. We will now...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

China Resources Building Materials Technology Holdings (SEHK:1313) has reported new engineered stone supply agreements with China Resources Land and renewed a multi year support services framework with CR Mixc Lifestyle, formalising ongoing intra group demand and operational links. See our latest analysis for China Resources Building Materials Technology Holdings. At a latest share price of HK$1.72, the stock has a 1 month share price return of 7.50% and a 1 year total shareholder return of...

CITIC Limited's ( HKG:267 ) price-to-earnings (or "P/E") ratio of 4.9x might make it look like a strong buy right now...

With recent shifts in the global economy, Asian markets have become a focal point for investors looking to navigate fluctuating conditions. Amid these developments, penny stocks—typically smaller or newer companies—remain an intriguing area of exploration for those seeking potential growth at lower price points. Despite being considered a somewhat outdated term, penny stocks continue to offer opportunities for discovering hidden value when backed by strong financials and fundamentals.

GR Life Style’s pivot toward AI healthcare GR Life Style (SEHK:108) has signed a cooperation memorandum with Mingzhi Medical Technology, aiming to link AI with oncology research and traditional Chinese medicine as it pivots away from a purely property-focused model. See our latest analysis for GR Life Style. The cooperation news comes after a sharp 32.14% 90-day share price return and a 9.75% 30-day share price return to HK$2.59. The 1-year total shareholder return of about 2.5x suggests...

Key Insights The projected fair value for Budweiser Brewing Company APAC is HK$13.96 based on 2 Stage Free Cash Flow to...

Kuaishou Technology ( HKG:1024 ) saw a double-digit share price rise of over 10% in the past couple of months on the...

OSL Group (SEHK:863) has launched a sizeable equity raise, combining a HK$1.56b private placement and follow on offering to fund its stablecoin and payments push and broader digital asset platform expansion. See our latest analysis for OSL Group. That equity raise lands after a sharp 15.56% 7 day share price decline and a 10.48% year to date share price fall, even though the 1 year total shareholder return is 58% and the 3 year total shareholder return is very large at roughly 3x. If this...

China Petroleum & Chemical Corporation recently reported its 2025 operating results, showing slightly higher crude oil and natural gas production but lower refinery throughput and reduced gasoline and diesel output compared with the prior year. The company’s downstream mix shifted, with jet-fuel-related kerosene and light chemical feedstocks increasing alongside higher ethylene and synthetic resin production, highlighting a tilt toward petrochemicals. We will now examine how this shift...

It's not a stretch to say that Xinji Shaxi Group Co., Ltd's ( HKG:3603 ) price-to-sales (or "P/S") ratio of 0.3x right...

JD Logistics, Inc. ( HKG:2618 ), might not be a large cap stock, but it received a lot of attention from a substantial...

There wouldn't be many who think C-MER Medical Holdings Limited's ( HKG:3309 ) price-to-sales (or "P/S") ratio of 0.9x...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...